By PPN News Staff
The FDA approved moxetumomab pasudotox-tdfk (Lumoxiti, AstraZeneca/MedImmune) injection for intravenous use to treat adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL, a rare, slow-growing hematologic malignancy in which the bone